XML 49 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)
 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended
Dec. 31, 2011
Oct. 31, 2011
Amendment
Mar. 31, 2014
Amendment
Advance the program following completion of Phase 2a
Dec. 31, 2012
Amendment
Advance the program following completion of Phase 2a
Mar. 31, 2012
Amendment
Advance the program following completion of Phase 2a
Jun. 30, 2014
Maximum
Amendment
Advance the program following completion of Phase 2a
Dec. 31, 2008
Glaxo, Smith, Kline
Project
Jun. 30, 2014
Glaxo, Smith, Kline
Mar. 31, 2014
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Jun. 30, 2014
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Dec. 31, 2013
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Expansion
Jun. 30, 2014
Glaxo, Smith, Kline
Maximum
Jun. 30, 2014
Glaxo, Smith, Kline
Maximum
Annual net sales milestones achieved
Dec. 31, 2013
Glaxo, Smith, Kline
Minimum
Oct. 31, 2011
Astra Zeneca
Sep. 30, 2006
Astra Zeneca
Jun. 30, 2014
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Jun. 30, 2014
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Dec. 31, 2013
Astra Zeneca
Sep. 30, 2013
National Institutes of Health
Hepatic Fibrosis and Cirrhosis
Jun. 30, 2012
National Institutes of Health
Autoimmune Disease
May 31, 2012
National Institutes of Health
Rheumatoid Arthritis
Jul. 31, 2011
National Institutes of Health
Skin Autoimmune Inflammation
Aug. 31, 2010
National Institute Of Allergy And Infectious Diseases
HBV
Sep. 30, 2008
National Institute Of Allergy And Infectious Diseases
ISS Technology
Product Information [Line Items]                                                            
Number of programs for research and early clinical development             4                                              
Potential milestone payment                             $ 125,000,000 $ 60,000,000                            
Collaboration Revenue   3,000,000 5,400,000 6,000,000 2,600,000   10,000,000 631,000   357,000 1,262,000 714,000               180,000 180,000 360,000 360,000              
Revenue from milestone payment 12,000,000         100,000,000               3,000,000           545,000 819,000 1,432,000 1,165,000              
Deferred revenue recognition period                             7 years   6 years 50 months       24 months                
Additional revenue recognized               300,000 300,000                                          
Deferred revenue               1,300,000     1,300,000   2,500,000             7,000,000   7,000,000   4,800,000            
Research collaboration and license agreement period                                     3 years                      
Grants receivable                                                 200,000 600,000 400,000 600,000 1,400,000  
Contract agreement period                                                           5 years
Contract awarded to develop technology                                                           $ 17,000,000